Fresenius Medical Care AG & Co. (ADR) (FMS) was Upgraded by Jefferies to ” Hold”. Earlier the firm had a rating of “Underperform ” on the company shares. Jefferies advised their investors in a research report released on Jul 8, 2016.
On the company’s financial health, Fresenius Medical Care AG & Co. (ADR) reported $0.75 EPS for the quarter, based on the information available during the earnings call on May 3, 2016. Analyst had a consensus estimate of $0.75. The company had revenue of $4205.00 million for the quarter, compared to analysts expectations of $4223.64 million. The company’s revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.69 EPS.
Fresenius Medical Care AG & Co. (ADR) closed down -0.32 points or -0.74% at $43.16 with 78,799 shares getting traded on Tuesday. Post opening the session at $43.37, the shares hit an intraday low of $43.06 and an intraday high of $43.47 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
Fresenius Medical Care AG & Co. KGaA (FMC AG & CO. KGAA) is a kidney dialysis company. The Company provides dialysis care services related to the dialysis treatment a patient receives with end-stage renal disease (ESRD) as well as other health care services. FMC AG & CO. KGAA also provides dialysis products for the treatment of ESRD which includes manufacturing and distributing products such as hemodialysis machines peritoneal cyclers dialyzers peritoneal solutions hemodialysis concentrates solutions and granulates bloodlines renal pharmaceuticals and systems for water treatment. The Company’s health care services referred to as care coordination services include pharmacy services vascular cardiovascular and endovascular specialty services non-dialysis laboratory testing services physician services hospitalist and intensivist services health plan services and urgent care services. The Company also offers a range of dialysis drugs.